drugset / Trial / NCT05498636
SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression
NaSingle-groupOpen-labelTreatment
Summary
This study is a phase II multi-center prospective clinical trail which investigates the efficacy and safety of Selinexor combined with prednisone, etoposide and lenalidomide in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patient with high p53 and/or c-myc expression.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2025-07-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | — | — |
| Subject | Lenalidomide | Other / unclassified | — | — |
| Subject | Prednisone | Other / unclassified | — | — |
| Subject | Selinexor | Other / unclassified | — | — |